How long do you take targeted drugs for lung cancer?
The time taken for targeted treatment of lung cancer needed to be considered from both the patient's own condition and the progression of the disease. For patients with middle-stage lung cancer, it is recommended to take the first-generation targeted drug for 1.5 - 2 years or the third-generation targeted drug for 3 years. For patients with advanced lung cancer, as long as the targeted drug was effective, it was recommended to take it until the disease progressed. If drug resistance appeared, the targeted drug would need to be replaced. However, it should be noted that the premise of using targeted drugs was that the patient must have a clear target for treatment in the body, and there must be a specific drug targeting the target before targeted drug therapy could be carried out. Less than 20% of lung cancer patients could find targeted drugs. Read more exciting novels for free
How long will it take for targeted drugs to be effective for lung cancer?
Patients with lung cancer usually took targeted drugs for ten days, no more than forty days, and the effect would take effect in two to three days. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is it always effective to take targeted drugs for lung cancer?
The effect of targeted drugs on lung cancer patients was not very good. Target drugs could not cure lung cancer. Although they could prolong survival time, they could not always be effective. There were very few driver mutations in lung cancer, so there were relatively few targeted drugs that could be used. When using targeted drugs, it was necessary to find the target of lung cancer and could not be used blindly. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
What are the targeted drugs for small cell lung cancer?
Currently, targeted drugs specifically for small cell lung cancer have not been approved for marketing, but there are other types of targeted drugs that can be used to treat small cell lung cancer. For example, anlotinib, a new small-molecular multi-target tropinase inhibition drug, has anti-tumor vasodification effects and has been used in the third-line treatment of small cell lung cancer; Nivaliumab was approved for the treatment of patients with metastasized small cell lung cancer who had previously received platinum-based chemotherapy and at least one other therapy; Drulimucomab can be used in combination with chemotherapy to treat extensive small cell lung cancer; Atelibiza can be used in combination with chemotherapy to treat first-line treatment of extensive small cell lung cancer; There were also apatinib, niraparik, pembrolizib, and so on. In addition, as an anti-viral and anti-tumor immune regulator, Interferon can be used in the treatment of lung cancer; Bendamustine is an egf-receptor antagonist, which can reduce the side effects of patients and achieve a certain effect; Imatini suppresses the growth of cancer cells, prolonging the survival of patients and reducing adverse reactions; Perindopril Fumarate is an oral neo-vasodilator, which can suppress tumor neo-vasodillations and slow down tumor growth. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is it effective to take targeted drugs after draining lung cancer in the late stage? How long is it effective?
For patients with late-stage lung cancer, the effectiveness of targeted drugs was related to many factors. The effectiveness of taking targeted drugs after draining the fluid could not be determined. First of all, an important prerequisite for targeted drugs to work was that genetic testing could find sensitive gene mutation sites. If the patient's genetic test results showed that there was a suitable target, the targeted drug could be effective. There was no direct causality between the operation of draining the fluid from late-stage lung cancer and the effectiveness of the targeted drug. Secondly, the duration of the targeted drug's effect on the patient also varied from person to person. Some patients may see obvious effects at the beginning of the drug, such as tumor shrinking, but due to the possible resistance of cancer cells, the effect may change over time. Some patients may have a good effect at first, but after a period of time (the specific length of time may vary from several months to several years), due to the adaptability of the cancer cells (such as replacing the cell pathway inhibited by the targeted drug through other pathways), the treatment effect will not be ideal. In addition, different types of lung cancer had different responses to targeted drugs. For example, the molecular characteristics of lung cancer were that even if genetic testing was done, common targets were rarely matched. In this case, the targeted drugs might not be effective. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
What is the survival rate of targeted drugs in the treatment of advanced lung cancer?
There was a large individual difference in the survival rate of patients with advanced lung cancer after taking targeted drugs. The time from the start of treatment to disease progression or death was 9.2 - 18.9 months, and the general overall survival period was 21.6 - 36 months. Some studies had shown that the average survival time for late-stage lung cancer patients with targeted drugs was about three years, but there were also cases where it was as short as one or two years and as long as ten years. According to the data, after comprehensive treatment, the 2-year survival rate of stage IUA lung cancer patients was 23%, the 5-year survival rate was 10%, and the medium survival time was 11.5 months. For stage IUA lung cancer patients who had multiple metastasies, the 2-year survival rate was 10%, and the medium survival time was 6 months. In addition, in some studies, the 1-year, 2-year, 3-year, 4-year, and 5-year overall survival rates of the control group (first-line therapy with a combination of a combination The patient's physical condition, the effect of the targeted therapy, whether the attitude was positive, the degree of cooperation with the treatment, whether the patient had underlying diseases, and the support, care, and financial investment of the family would all affect the survival rate. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is it useful to take targeted drugs for esophagus cancer metastasizing?
At present, a variety of targeted drugs were available for the treatment of esophagus cancer, including new small molecules multi-target Tyrosin Kinase Inhibition, drugs that targeted HEL2, cetuxed that targeted the egFr target, and bevacizumb that targeted the veg-like growth factor target, etc. There was also a combination of PD1 - 1 inhibition and targeted HEL2 for the treatment of cancer at the gastric-esophagus junction. Chinese studies have shown that as a new small-molecular multi-target Tyrosinase Kinase Inhibition, anlotinib and apitini have a certain effect in the treatment of esophagus cancer. The combination therapy of trastuzumab-targeted to HEL2 and PD1 inhibition drugs (such as pembrolizumab) combined with chemotherapy can be used as the first-line treatment for cancer of the gastroesophagus junction, advanced gastric cancer with HEL2 positive, and esophagus cancer. In the second-line treatment of China guidelines for the treatment of esophagus cancer, level II recommendations were given to anlotinib (Class 2A) and apitini (Class 3). However, there were no phase III clinical trials to prove that molecular targeted drugs could prolong the survival of patients with esophagus cancer. The effect of targeted therapy needed further study. In general, molecular targeted therapy had a certain clinical value for the treatment of patients with esophagus cancer, including those with metastasizing, but it still needed further in-depth research. These drugs must be used under the guidance of a professional doctor. It is not recommended for patients to buy and take them themselves to avoid serious adverse reactions. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Does lung cancer have targeted drugs that need to be taken all the time?
Whether or not targeted drugs for lung cancer needed to be taken all the time could not be said to be the same. On the one hand, targeted drugs may face the problem of drug resistance in cancer cells during treatment. Due to the rapid evolution of cancer cells, new genetic mutations may occur during the targeted drug treatment to avoid the targeted drug attack, resulting in drug resistance in the body. Once this happens, the targeted drug may not be able to continue to effectively suppress tumor growth. At this time, it may be necessary to change the treatment plan, such as switching to other targeted drugs or changing to chemotherapy. On the other hand, if the patient had a good response to the targeted drug and did not have any serious adverse reactions or drug resistance, from the perspective of continuous suppression of tumor cell growth and prevention of cancer relapse and migration, it might be necessary to continue taking the targeted drug to maintain the treatment effect. At the same time, factors such as the patient's actual disease progression and overall physical condition would also affect the duration of the targeted drug's use. The specifics should be determined according to the diagnosis of a professional doctor. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is it useful to take targeted drugs when cancer has ascitic fluid? How long is it?
Some targeted drugs had a certain effect on cancer ascitic fluid. For example, abdominal infusion of bevacizhu combined with chemotherapy could effectively reduce the accumulation of fluid in the abdominal cavity and control the production of abdominal fluid, but it was not clear how long it would take effect. For patients with liver cancer and hepatic ascitic fluid, targeted drugs such as sorafenib or lenvafenib may have a certain treatment effect, but there are also individual differences, and the specific time of effect cannot be determined. When using targeted drugs to treat ascitic fluid, it should be carried out under the guidance of a professional doctor. At the same time, it was necessary to actively treat the primary disease, strengthen nutrition, and pay close attention to the side effects of the drug. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
70-year-old advanced lung cancer can live for a few years with targeted drugs
For patients with late-stage lung cancer who took targeted drugs, the time from the start of treatment to the progression of the disease or the patient's death was 9.2 to 18.9 months. The general overall survival period was 21.6 to 36 months. There was also data that showed that the average survival time was about three years, but this was only a rough range. The specific situation needs to be determined based on the patient's physical condition (such as whether the patient has cardiovascular diseases, chronic rheumatism, liver diseases, and other basic diseases), the effect of targeted therapy, the patient's attitude and degree of cooperation with the treatment, as well as the support, care, and economic investment of the family members. There are individual differences. Some studies had shown that after comprehensive treatment, the 2-year survival rate of stage IUA lung cancer patients was 23%, the 5-year survival rate was 10%, and the mean survival time was 11.5 months. For stage IUA lung cancer patients who had multiple metastasies, the 2-year survival rate was 10%, and the mean survival time was 6 months. In addition, with the deepening of targeted drug research, more efficient targeted drugs could effectively prolong the survival of patients with advanced lung cancer. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
A year after taking targeted drugs for lung cancer, my sternum hurts a little
A year after a lung cancer patient took the targeted drug, there could be a variety of reasons for the pain in the sternum. On the one hand, this may be a side effect of the targeted drug. For example, gefitini may cause chest pain, which is usually mild and may gradually reduce as the drug continues to be used. On the other hand, lung cancer itself could also cause chest pain, especially when the disease progressed to the late stage. In addition, if the patient also had heart disease, such as heartache, similar symptoms might appear. Therefore, it was recommended that patients who experienced stabbing pain in their sternum should seek medical attention in time for a detailed examination. The doctor would conduct a comprehensive analysis based on the patient's specific condition, combined with factors such as drug use history and disease history to determine the specific cause of the stinging pain. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>